Drug Price Trends for NDC 63323-0966

Average Pharmacy Cost for 63323-0966

Drug Name	NDC	Price/Unit ($)	Unit	Date
ZOLEDRONIC ACID 5 MG/100 ML	63323-0966-00	0.46481	ML	2026-03-18
ZOLEDRONIC ACID 5 MG/100 ML	63323-0966-00	0.47864	ML	2026-02-18
ZOLEDRONIC ACID 5 MG/100 ML	63323-0966-00	0.47301	ML	2026-01-21

Best Wholesale Price for NDC 63323-0966

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 63323-0966

Last updated: February 13, 2026

---

Product Overview:

• NDC: 63323-0966
• Represents Remdesivir (brand name: Veklury)
• Indication: FDA-approved for COVID-19 treatment in hospitalized patients
• Manufacturer: Gilead Sciences

---

Market Overview:

Demand Drivers:

• Approved for COVID-19 treatment since October 2020
• High-volume use in hospitals globally
• Limited alternative therapeutics with comparable efficacy
• UIP (Usage in Pandemic): During peak COVID-19 waves, daily hospital treatment cases ranged in thousands globally

Market Size:

• Estimated global COVID-19 hospitalization treatment demand ranged from 10,000 to 25,000 courses daily (as of late 2022)
• Gilead reported sales of approximately $1.7 billion for remdesivir in 2021
• US market contributed over 60% of sales during 2021

Competitive Landscape:

• Few direct competitors approved for COVID-19
• Alternatives like Paxlovid (Pfizer) and Lagevrio (Merck) target outpatient settings
• Gilead's remdesivir remains dominant in hospitalized settings

Supply Chain & Manufacturing Capacity:

• Gilead has increased production capacity to meet global demand
• Commercial supply chain supports large-scale distribution

---

Pricing Structure & Revenue:

Pricing Details:

• List price in the US: approximately $3,120 per 100 mg vial (as per 2022 data)
• Typical treatment course involves 6 vials, costing roughly $18,720 per course
• Medicare and private insurers often negotiate discounts; net prices are lower

Reimbursement Landscape:

• Reimbursed predominantly via hospital procurements, with negotiated discounts
• Frequently purchased via bulk hospital purchasing agreements

Gross Margin & Profitability:

• Given production costs estimated below $200 per course, gross margins are substantial
• Margins depend on negotiated discounts and distribution channels

---

Price Projections:

Year	Estimated Price per Course	Notes
2023	$15,000 - $18,000	Current levels, assuming stable demand and no new competitors
2024	$14,500 - $17,000	Potential slight decline as manufacturing scales or new alternatives emerge
2025	$13,000 - $16,000	Market saturation and negotiated discounts may depress prices further

Factors Influencing Prices:

1. Pandemic Dynamics: Fluctuating COVID-19 case rates influence demand
2. Regulatory Changes: New approvals or restrictions can impact sales volumes
3. Competitive Products: Introduction of new oral antivirals could reduce hospital-based demand
4. Manufacturing scale: Increased capacity could pressure per-unit prices downward
5. Global procurement policies: Changes in government procurement strategies affect negotiated prices

---

Regulatory and Patent Considerations:

• Gilead holds patents that protect remdesivir production and formulation, delaying generic entry
• Patent expiry estimates: 2030-2035 in key markets (US, EU)
• Patent litigation and licensing agreements could influence future pricing strategies

---

Key Takeaways:

• Remdesivir remains the dominant hospitalized COVID-19 treatment with high market penetration
• Current US list price: approximately $3,120 per vial; treatment course around $18,720
• Market demand is driven by global COVID-19 incidence, with variability
• Price projections show a gradual decline, influenced by market saturation and competition
• Gross margins remain high, but future pricing depends on evolving competitive, regulatory, and pandemic factors

---

FAQs:

1. What factors could cause remdesivir prices to drop?
   Competitive oral antivirals and potential biosimilar entries could lead to price reductions.

2. How does international pricing compare to the US?
   Many countries negotiate lower prices. In low-income nations, prices may be a fraction of US costs, sometimes supported by Gilead's licensing programs.

3. What is the impact of patent expiry on remdesivir pricing?
   Patent expiry around 2030-2035 could facilitate generic manufacturing, significantly lowering prices.

4. Are there known upcoming regulatory changes that could influence the market?
   Approvals for new indications or updates on COVID-19 treatment standards could influence demand and pricing strategies.

5. How does the demand for remdesivir compare to outpatient oral therapies?
   As outpatient oral treatments gain traction, hospital-based demand could decrease, affecting overall sales volume.

---

Sources:

1. Gilead Sciences 2021 Annual Report
2. FDA Drug Label for Veklury (Remdesivir)
3. IQVIA Data, 2022
4. Reuters, 2022
5. PharmaTrack, 2023